BACKGROUND: The management of schizophrenia has seen significant strides over the last few decades, due to the increasing availability of a number of antipsychotics. Yet, the diminished efficacy in relation to the negative and cognitive symptoms of schizophrenia, and the disturbing adverse reactions associated with the current antipsychotics, reflect the need for better molecules targeting unexplored pathways. PURPOSE: To review the salient features of the recently approved antipsychotics; namely, iloperidone, asenapine, lurasidone and blonanserin. METHODS: We discuss the advantages, limitations and place in modern pharmacotherapy of each of these drugs. In addition, we briefly highlight the new targets that are being explored. RESULTS: Promising strategies include modulation of the glutamatergic and GABAergic pathways, as well as cholinergic systems. CONCLUSIONS: Although regulatory bodies have approved only a handful of antipsychotics in recent years, the wide spectrum of targets that are being explored could eventually bring out antipsychotics with improved efficacy and acceptability, as well as the potential to revolutionize psychiatric practice.
BACKGROUND: The management of schizophrenia has seen significant strides over the last few decades, due to the increasing availability of a number of antipsychotics. Yet, the diminished efficacy in relation to the negative and cognitive symptoms of schizophrenia, and the disturbing adverse reactions associated with the current antipsychotics, reflect the need for better molecules targeting unexplored pathways. PURPOSE: To review the salient features of the recently approved antipsychotics; namely, iloperidone, asenapine, lurasidone and blonanserin. METHODS: We discuss the advantages, limitations and place in modern pharmacotherapy of each of these drugs. In addition, we briefly highlight the new targets that are being explored. RESULTS: Promising strategies include modulation of the glutamatergic and GABAergic pathways, as well as cholinergic systems. CONCLUSIONS: Although regulatory bodies have approved only a handful of antipsychotics in recent years, the wide spectrum of targets that are being explored could eventually bring out antipsychotics with improved efficacy and acceptability, as well as the potential to revolutionize psychiatric practice.
Authors: Stefania Risso Bradley; Jelveh Lameh; Linda Ohrmund; Thomas Son; Abhishek Bajpai; Derek Nguyen; Mikael Friberg; Ethan S Burstein; Tracy A Spalding; Thomas R Ott; Hans H Schiffer; Ali Tabatabaei; Krista McFarland; Robert E Davis; Douglas W Bonhaus Journal: Neuropharmacology Date: 2009-10-14 Impact factor: 5.250
Authors: Simon Sydserff; E J Sutton; Dekun Song; Michael C Quirk; Carla Maciag; Chaoying Li; Gerald Jonak; David Gurley; John C Gordon; Edward P Christian; James J Doherty; Tom Hudzik; Edwin Johnson; Ladislav Mrzljak; Tim Piser; Gennady N Smagin; Yi Wang; Dan Widzowski; Jeffrey S Smith Journal: Biochem Pharmacol Date: 2009-07-16 Impact factor: 5.858
Authors: S Volpi; C Heaton; K Mack; J B Hamilton; R Lannan; C D Wolfgang; L Licamele; M H Polymeropoulos; C Lavedan Journal: Mol Psychiatry Date: 2008-06-03 Impact factor: 15.992
Authors: Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero Journal: Eur Neuropsychopharmacol Date: 2014-08-01 Impact factor: 4.600
Authors: Maxine Zhou; Sahar Derakhshanian; Alexander Rath; Sarah Bertrand; Caroline DeGraw; Rachel Barlow; Aja Menard; Adam M Kaye; Jamal Hasoon; Elyse M Cornett; Alan D Kaye; Omar Viswanath; Ivan Urits Journal: Psychopharmacol Bull Date: 2020-09-14